This presentation hosts the first findings to measure the effect of Doxy-PEP at the population level, showing a substantial and sustained decline in the number of chlamydia and early syphilis infections in the city among men who have sex with men and transgender women over the 13 months after the...
This video presentation by the San Francisco Department of Public Health (SFDPH) on implementation of Doxy-PEP in a single clinic which offered Doxy-PEP to all clients using HIV PrEP and saw bacterial STIs decrease among those who used Doxy-PEP by nearly 60% in less than a year, with the highest...
This guideline discusses the interim recommendations for the use of doxycycline for post-exposure prophylaxis (doxy PEP) for the prevention of certain bacterial sexually transmitted infections (STIs).
This fact sheet from the NYC Department of Health and Mental Hygiene discusses how Doxy PEP can be used for STI prevention.
This fact sheet discusses how doxy PEP can be used for STI prevention.
This webpage discusses how using doxycycline as STI PEP (post-exposure prophylaxis) is a new use for a well-known medication. Learn more about this new tool and how it's being used to prevent STIs!
This recorded presentation delves into the critical issue of STI disparities among adolescents in the Southern United States, a pressing public health concern with significant implications for health equity. Understanding these disparities is essential for developing effective interventions and...
This video discusses how during the 2024 Conference on Retroviruses and Opportunistic Infections, Dr. John Brooks, Chief Medical Officer for CDC's Division of HIV Prevention, joins HIV.gov Director Miguel Gomez to share the latest information on mpox.
In this video, the day before the 81st Presidential Advisory Council on HIV/AIDS (PACHA) started, Dr. Jonathan Mermin, Director of the National Center for HIV, Viral Hepatitis, STD, and TB Prevention at CDC, spoke with HIV.gov Director Miguel Gomez about the recently released Doxy PEP clinical...
